Cabaletta Bio
Clinical trials sponsored by Cabaletta Bio, explained in plain language.
-
Could CAR t cells calm scleroderma? new trial launches.
Disease control Recruiting nowThis early-phase trial tests a treatment called CABA-201, which uses a patient's own immune cells (CAR T cells) to target and destroy certain immune cells that may drive systemic sclerosis (scleroderma). The study aims to see if this approach is safe and can reduce disease activi…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
CAR t cells take on muscle disease: new hope for myositis patients
Disease control Recruiting nowThis study tests a new treatment called CABA-201 for people with active inflammatory muscle diseases (myositis). The treatment uses a patient's own immune cells, modified to target and destroy certain immune cells that cause the disease. The goal is to see if it is safe and can r…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Engineered immune cells take aim at blistering skin disease
Disease control Recruiting nowThis study tests two types of modified immune cells (CAR T-cells) in 40 adults with active pemphigus vulgaris, a painful blistering condition. The cells are designed to target and destroy the immune cells causing the disease. The main goal is to check safety and find the right do…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC